Peter Lawrence, Cardurion CEO; Adam Koppel, Bain Capital Life Sciences managing director
A quiet cardio upstart makes some noise, getting $300M from Bain and diving deep into the clinic — with some real money for pipeline deals
The small executive team at Cardurion has been sticking carefully to its goals, in-licensing a lead cardio drug from Astellas in 2018 and making a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
